Skip to main content
OpenTrials
Completed

NCT Number: NCT04891393

The Effects of Caffeine on Human Spinal Motoneurons

This study evaluates the effects of orally ingested, commercially available, coffee (3 mg/kg of caffeine) on the excitability of human spinal motoneurons of the lower leg.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Temple University

Philadelphia, Pennsylvania, 19122, United States

About this study

Recently, it has been shown that human spinal motoneurons do not simply act as a binary control system. Instead, they are regulated by intrinsic properties that can elicit lingering effects on the descending motoneuron. Caffeine, one of the world's most popular over-the-counter supplements, can potentially augment these characteristics of motoneurons. Using decomposition software and non-invasive, high-density surface electromyography, it is possible to extract the characteristics of these motoneurons. This project will utilize a double-blind, inactive-placebo controlled, crossover design study to examine and quantify the effects of caffeine on motoneuron excitability.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

● Between 18 and 70 years of age

Exclusion criteria

  • Significant neurological or orthopedic injuries, which may limit volitional torque generation in the tested muscles.
  • Significant change in the subjects' health or treatment in the past month.
  • Known history of cardiovascular pathology (to include: uncontrolled hypertension, cardiac arrhythmias) or medical restrictions to caffeine ingestion.
  • Allergies or dislike of coffee.
  • Women who are pregnant will be excluded due to potential forces at trunk from pelvic safety harness and due to potential adverse effects of caffeine on the developing child.
  • Women who are breastfeeding will be excluded due potential adverse effects on the breastfeeding infant from caffeine administration.
  • Adults unable to consent, minors, pregnant women, and prisoners will not be included.

Treatment and study plan

Coffee

Dietary Supplement

Starbucks brand "Via" instant coffee. (Caffeine Content: 3 mg / kg)

Decaffeinated coffee

Dietary Supplement

Starbucks brand "Via" instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)

Primary outcomes

  1. Motoneuron excitability (Delta-f)

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

    Changes in motorneuron excitability, as quantified by Delta-F values. A paired motor unit technique will be utilized (Gorassini et al., 2002). (Typically, these values range from -5 to +10).

Secondary outcomes

  1. Motor Unit Discharge Rate

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

    Changes in motor unit discharge rate. This is a single value that ranges from, approximately, 0 to 30.

  2. Coherence

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

    Changes in coherence values. Coherence provides a normalized value of the strength of correlation in the frequency domain. The magnitude of the correlation of the Fourier transforms of two spike trains is squared producing a value between 0 and 1, with 1 corresponding to a perfect linear prediction at a particular frequency (Rosenberg et al., 1989). This will be calculated using the composite spike train (Negro & Farina, 2012) and, finally, z-transformed to allow for between-trial comparisons.

  3. Motor Unit Recruitment Threshold

    Time frame: Measured repeatedly at set intervals; Pre-Intervention & 30, 60, 90 minutes post-Intervention

    Changes in motor unit recruitment threshold. As assessed by determining the amount of force (percentage of maximum volitional force output) needed to recruit an individual motor unit.

Sponsors and collaborators

Lead sponsor

Temple University

Other

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
May 18, 2021
Registry last updated
Apr 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.